-
Imatinib inhibits the BCR/ABL tyrosine kinase in CML, leading to improved responses over standard therapy. This report provides 5 year follow-up from the seminal IRIS study of upfront imatinib for chronic phase CML among the 553 patients randomized to 400 mg of imatinib.
-
Trastuzumab has previously been demonstrated to be active against HER2 positive breast cancer when used in the metastatic setting.
-
In a family-based research cohort, men were followed for up to 40 years after the birth of their children, and those with only daughters had a 40% higher risk of prostate cancer compared with men with at least one son.
-
Breast cancer statistics indicate a rapid decrease in prevalence immediately after the publicity surrounding the reports from the Women's Health Initiative.
-
Breast cancers that are "triple-negative" (ie, ER, PR, HER2-negative) are considered high risk, yet there remains variability, with some demonstrating less malignant features than others.
-
Several important papers have been published in the last 2 months, none more important than the realization that breast cancer rates have dropped precipitously since the publication of the Women's Health Initiative (WHI) in 2002.
-
-
Lacey and colleagues from the National Cancer Institute reported the results of postmenopausal hormone exposure in a cohort study with 214 cases of ovarian cancer.1 The over-all cohort of 97,368 women constituted the NIH-AARP Diet and Health Study.
-
Drug Labels A Prescription for Misunderstanding?; Osteonecrosis of the Jaw New Side-Effect to Bisphosphate Use; Beta-Blockers and Depression Unlinked?; FDA Actions
-
